Response of Favus to Griseofulvin

Cardiovascular effects of griseofulvin.

The intravenous administration of griseofulvin in doses of 3.0 mg/kg to 32 anesthetized open-chest dogs produced marked increments (43%) in isometric systolic force measured by a strain gauge. These changes were accompanied by an increase (22%) in heart rate and a decrease (25%) in blood pressure. The effect was unaltered by clamping the blood supply to and from the adrenal glands or by previou...

The chemistry of griseofulvin.

Hepatocareinogenicity of Griseofulvin following Parenteral Administration to Infant Mice1

Random-bred infant Swiss mice were injected subcutaneously with suspensions of griseofulvin in tricaprylin according to various dosage schedules. Doses of griseofulvin in excess of 0.25 mg on Day 1 of life produced acute toxicity. Following a total dosage of 3.0 mg in infant mice. 0.5, 0.5, 1.0, and 1.0 mg at ages of 1, 7, 14, and 21 days, respectively, a high incidence of hepatomata, in 44% of...

Oral griseofulvin: a cocarcinogenic agent to methylcholanthrene induced cutaneous tumors.

Since certain antitumor drugs also arrest mitosis in metaphase, an attempt was made to determine the effect of oral griseofulvin on methylcholanthrene-induced cutaneous tumors in mice. Contrary to expectations, mice on large doses (1000-1500 mg/kg) of griseofulvin subjected to methylcholanthrene applications had a shorter tumor lag period and developed more and larger tumors than did mice not r...

Ketoconazole in griseofulvin-resistant dermatophytosis.

The efficacy of ketoconazole was evaluated in twenty patients with chronic dermatophyte infections who had failed to clear with griseofulvin therapy. Trichophyton rubrum was the causative organism in nineteen of the patients, and Trichophyton mentagrophytes in one patient. Three of twelve organisms tested showed in vitro resistance to griseofulvin. Duration of infection ranged from 2 to 28 year...